

Corporate Deal Trends

A Look at the M&A, Licensing and Financing Landscape in 2025

Overview

Approaching the halfway point of 2025, panelists shared industry, legal and finance perspectives on deal trends, opportunities and market outlook for transactions in the Life Sciences industry. Topics included trends in deal structures, the biotech IPO market, alternative financing structures, notable therapeutic areas, technologies and modalities, impacts of the new administration, and more trends to watch in the coming year.

Panel Questions

1. How is the current level of macroeconomic uncertainty impacting deals and deal flow from your perspective?
2. How are biotech companies evaluating options for funding in the current environment?
3. What factors are impacting decision-making on transactions for pharmaceutical companies?
4. How are risks around antitrust, drug pricing and other policy changes playing into decision-making for companies and investors?
5. How are companies and investors viewing the recent federal funding cuts and agency reductions? Do you expect long-term impact on innovation and pipelines in the U.S.?
6. If the U.S. pipeline does contract, where can we expect to see continued or increasing activity?

Additional Resources

- [How will Smaller, Smarter Deals Help Life Sciences Companies Shape the Future with Confidence? | EY M&A Firepower Report 2025](#)
- [Healthcare's Path Forward: The Key Trends Shaping 2025 | Jefferies Editorial Team](#)

Panel



Julianne Hearn (Moderator)

Of Counsel, Boston
+1 617 603 8888
jhearn@cov.com



Dr. Bryan Czyzewski

Managing Director in Healthcare
Investment Banking, Jefferies



Janet Raimondo

Global Head Legal Transactions,
Novartis Corporation



Wendell Taylor

Chief Corporation Counsel,
Biogen



Robin Walker

Chief Legal Officer and Corporate
Secretary, Areteia Therapeutics

